Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer

Cancer Prevention Research

Volumn 6, Issue 5, 2013, Pages 437-447

  Wang, Chunmei ^a   Schwab, Luciana P ^b   Fan, Meiyun ^a,b   Seagroves, Tiffany N ^a,b   Buolamwini, John K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DIPYRIDAMOLE; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VASODILATOR AGENTS; WEIGHT GAIN;

EID: 84877306347     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0345     Document Type: Article

References (48)

1. Crowell JA. The chemopreventive agent development research program in the division of cancer prevention of the U.S. National Cancer Institute: an overview. Eur J Cancer 2005; 41:1889-910. (Pubitemid 41557676)
2. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA-A Cancer J Clin 2004; 54:150-80. (Pubitemid 38812180)
3. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976; 36:2699-702.
4. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 78:199-334.
5. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005; 111:650-6. (Pubitemid 40216494)
6. Taylor AL, Adams-Campbell LL, Wright JTJr. Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress? J Natl Cancer Inst 1999; 91:1792-3.
7. Jemal A, Siegel R, Ward E, Murray T, Xu JQ, Thun MJ. Cancer statistics, 2007. CA-A Cancer J Clin 2007; 57:43-66. (Pubitemid 46148091)
8. Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska natives. Cancer 2007; 110: 2119-52. (Pubitemid 350100734)
9. Thomsen A, Kolesar JM. Chemoprevention of breast cancer. Am J Health Syst Pharm 2008; 65:2221-8.
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90:1371-88. (Pubitemid 28439961)
11. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999; 281:2189-97. (Pubitemid 29275701)
12. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modifiedrelease dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii-iv, 1-196.
13. Chakrabarti S, Freedman JE. Dipyridamole, cerebrovascular disease, and the vasculature. Vascul Pharmacol 2008; 48:143-9.
14. Saravanan K, Barlow HC, Barton M, Calvert AH, Golding BT, Newell DR, et al. Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of alpha1-acid glycoprotein. J Med Chem 2011; 54:1847-59.
15. Smith PG, Marshman E, Newell DR, Curtin NJ. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. Br J Cancer 2000; 82:924-30. (Pubitemid 30085247)
16. Drago JR, Curley RM, Sipio JC. Nb rat prostate adenocarcinoma model: metastasis. Anticancer Res 1985; 5:193-6.
17. Tzanakakis GN, Agarwal KC, Vezeridis MP. Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233. Cancer 1993; 71:2466-71. (Pubitemid 23100478)
18. Choudhary S, Sood S, Wang HC. Dipyridamole intervention of breast cell carcinogenesis. Mol Carcinog 2012 Oct 16. [Epub ahead of print].
19. Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, et al. Dipyridamole prevents triple-negative breast-cancer progression. Clin Exp Metastasis 2013; 30:47-68.
20. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8:R76.
21. Lin EY, Jones JG, Li P, Zhu UY, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163:2113-26. (Pubitemid 37310040)
22. Ullman-Cullere MH, Foltz CJ. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 1999; 49:319-23. (Pubitemid 29284390)
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64.
24. Willson JK, Fischer PH, Tutsch K, Alberti D, Simon K, Hamilton RD, et al. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res 1988; 48: 5585-90.
25. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 2011; 13:212.
26. Zetter BR. Adhesion molecules in tumor-metastasis. Semin Cancer Biol 1993; 4:219-29.
27. Sumitomo M, Shen RQ, Walburg M, Dai J, Geng YP, Navarro D, et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 2000; 106: 1399-407.
28. Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K, et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 2000; 6:1647-54. (Pubitemid 30305056)
29. Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V, et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011; 30:1318-28.
30. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007; 26:3279-90. (Pubitemid 46763021)
31. Ellinger-Ziegelbauer H, Kelly K, Siebenlist U. Cell cycle arrest and reversion of Ras-induced transformation by a conditionally activated form of mitogen-activated protein kinase kinase kinase 3. Mol Cell Biol 1999; 19:3857-68. (Pubitemid 29193845)
32. Rebbeck TR, De Michele A, Tran TV, Panossian S, Bunin GR, Troxel AB, et al. Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women. Carcinogenesis 2009; 30:269-74.
33. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996; 56:3371-9. (Pubitemid 26242991)
34. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1998; 58:4782-6. (Pubitemid 28503667)
35. White NMA, Chow TFF, Mejia-Guerrero S, Diamandis M, Rofael Y, Faragalla H, et al. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 2010; 102:1244-53.
36. Hayami T, Shukunami C, Mitsui K, Endo N, Tokunaga K, Kondo J, et al. Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 1999; 458:436-40. (Pubitemid 29433850)
37. Shukunami C, Hiraki Y. Expression of cartilage-specific functional matrix chondromodulin-1 mRNA in rabbit growth plate chondrocytes and its responsivenesstogrowth stimuli invitro. Biochem Biophys Res Commun 1998; 249:885-90. (Pubitemid 28441933)
38. Wells WA, Schwartz GN, Morganelli PM, Cole BF, Gibson JJ, Kinlaw WB. Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat 2006; 98:231-40. (Pubitemid 44050774)
39. Chung HJ, Levens D. c-myc expression: keep the noise down! Mol Cells 2005; 20:157-66.
40. Drabovich AP, Pavlou MP, Dimitromanolakis A, Diamandis EP. Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay. Mol Cell Proteomics 2012; 11:422-34.
41. Sameen S, Khalid Z, Malik SI. Role of pyruvate dehydrogenase kinases (PDK's) and their respective microRNA's in human ovarian cancer. J Med Genet Genomics 2011; 3:115-21.
42. Yamamoto Y, Yoshioka Y, Minoura K, Takahashi RU, Takeshita F, Taya T, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer 2011; 10:135.
43. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28:341-7.
44. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZGC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137:1032-46.
45. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011; 71:78-86.
46. Zhou CC, Liu JB, Li Y, Liu L, Zhang XJ, Ma CY, et al. Micro RNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma. FEBS Lett 2011; 585:1828-34.
47. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer (vol 449, pg 682, 2007). Nature 2008; 455:256.
48. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115:787-98. (Pubitemid 38058492)